Smarter in Minutes #5: Molnupiravir*** Pre-Assessment*** Survey

Before you view the activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit.

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit. There is no fee to participate in this activity.

2.In what type of patients should molnupiravir be considered as a COVID-19 treatment?(Required.)

Elderly patients

Pediatric patients

Pregnant or lactating women

3.The disadvantage of using MOL versus PAX or RDV for COVID-19 infections in the outpatient setting is:(Required.)

Requires BID dosing

Requires admin. via a nasogastric tube

More severe AE profile

Lower clinical efficacy

4.67-year-old male w/ Grade 4 CKD outpatient with COVID-19 symptom onset ≤5 days, tests positive for SARS-CoV-2 by PCR. Which antiviral do you recommend?(Required.)

Paxlovid

Molnupiravir

Remdesivir

Sotrovimab

5.Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity).

First Name

Last Name

Degree/Credentials

State/Province

ZIP/Postal Code

Country

Email Address (required to receive credit)